Ask me later

Ask me later

How likely are you to recommend Redeye to a friend or colleague?

1

2

3

4

5

6

7

8

9

10

Not likely

Very likely

Not likely

1

2

3

4

5

6

7

8

9

10

Very likely

Message received

Thanks again for rating us!

Cereno Scientific: First-patient-in and updated study timeline

Premium Plan required to unlock

Unlock companies to access

more high quality research.

Redeye is encouraged by Cereno Scientific announcing first-patient-in for its phase II study with lead candidate CS1 in PAH. Further, the company updated its guidance on top-line data, now expected in Q1 2023 (Q4 2022).

CB

Christian Binder

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.